Literature DB >> 28382815

177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Michael S Hofman1, Michael Michael1, Rodney J Hicks1,2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28382815     DOI： 10.1056/NEJMc1701616

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.

Authors:  Sue Ping Thang; Mei Sim Lung; Grace Kong; Michael S Hofman; Jason Callahan; Michael Michael; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-12       Impact factor: 9.236

Review 2.  Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.

Authors:  Melpomeni Fani; Rosalba Mansi; Guillaume P Nicolas; Damian Wild
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

3.  Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5.

Authors:  Rosalba Mansi; Guillaume Pierre Nicolas; Luigi Del Pozzo; Karim Alexandre Abid; Eric Grouzmann; Melpomeni Fani
Journal:  Molecules       Date:  2020-09-11       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.